Frontlight ResearchEarly access
Taking people in FrancePhase 3
Tests aprepitant effect on aldosterone in sleep apnea with high blood pressure
Tests aprepitant on aldosterone levels in adults with sleep apnea and high blood pressure.
Key facts
- Who runs it
- Centre Hospitalier Universitaire Rouen
- Where
- Rouen Cedex, FranceSee the site
- Registry title
- PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST, APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME - (APHOS3)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 24 people, planned
- Started
- 1 Jul 2024
- Expected to end
- 19 Apr 2027
- Type of study
- Interventional
- Record updated
- 18 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with severe obstructive sleep apnea and high blood pressure. It tests whether aprepitant changes aldosterone levels.
- Age
- 18 to 75 years
- Sex
- Women and men can join.
- Disease stage
- Severe obstructive sleep apnea (apnea and hypopnea index of 30/h or more) and essential high blood pressure (SBP 140 or more and/or PAD 90 mmHg or more), treated or newly diagnosed.
- Earlier treatment
- Diuretics must be replaced with another neutral blood pressure drug that does not affect the renin-angiotensin system, before the trial drug and during the study.
Main reasons for not taking part
- Severe uncontrolled heart or brain vessel disease, such as heart attack or stroke in the last 6 months, unstable angina or heart failure
- Chronic kidney failure or moderate liver failure
- Epilepsy
- Known acute infection with HIV, HBV or HCV
- Active cancer under treatment or treatment that suppresses the immune system
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Subject with severe obstructive sleep apnea syndrome defined by an apnea and hypopnea index (AHI) ≥ 30/h in polysomnography or ventilatory polygraphy (requiring continuous positive pressure equipment)
- Subject with essential hypertension treated medically or by lifestyle and dietary measures or newly diagnosed (defined by SBP ≥ 140 and/or PAD ≥ 90 mmHg according to current SFHTA-HAS recommendations)
- Patient's agreement to replace diuretics with another neutral antihypertensive treatment (which does not interfere with the reninangiotensin system) before taking the experimental treatment and throughout the study (if applicable)
- Regulatory Criteria: o Adult aged 18 to 75 / o Affiliation to a social security scheme / o Person who has read and understood the information letter and signed the consent form / o For women: - of childbearing age, need for effective mechanical contraception (condoms) during the study and within 2 months of the last month taken, with a negative urine pregnancy test on inclusion and for the duration of the study study at V2 and V4, - postmenopausal: amenorrhea not medically induced for at least 12 months before the V1 visit
Who cannot take part
- Criteria for aprepitant: o Hypersensitivity to the active substance (aprepitant) or/and one of the excipients (contents and capsule shell) o People with hereditary problems of fructose intolerance, glucosegalactose malabsorption syndrome, or sucrase/isomaltase deficiency o Subject treated with drugs metabolized by cytochromes CYP3A4 and CYP2C9: corticosteroids (dexamethason, methylprednisolone), anti vitamin K (warfarin, acenocoumarol), benzodiazepines (midazolam, alprazolam, triazolam), anti-depressants (nefazodone), quinidine, hormonal contraceptives , ergot alkaloids (ergotamine, diergotamine), immunosuppressants (ciclosporin, tacrolimus, sirolimus, everolimus), morphine (alfentanil, fentanyl), antibiotics (rifampicin and clarithromycin-type macrolides, telithromycin), azole antifungals (ketoconazole, itraconazole, voriconazole, posaconazole), anti-virals (protease inhibitors), anti-epileptics (phenytoin, carbamazepine, phenobarbital), chemotherapies (etoposide, vinorelbine, ifosfamide, irinotecan), diuretics (tolbutamide) and herbal preparations containing St. John's wort. As well as these molecules in co-administration pimozide, terfenadine, astemizole and cisapride
- Criteria relating to associated pathologies leading to particular risks: o Subject with excessive daytime sleepiness with a contraindication to driving (Epworth score > 16) / o Severe uncontrolled cardiovascular disease: myocardial infarction or stroke in the last 6 months, unstable angina, heart failure. / o Knowledge of chronic renal failure defined by a glomerular filtration rate < 60 mL/min/1.73m2 for more than 3 months) or moderate hepatic failure defined by ALT and/or AST transaminases > 3N) / o Epilepsy o Known acute infections related to HIV, HBV or HCV / o Active cancer undergoing treatment or immunosuppressive treatments
- Minor subject or subject over 75 years old
- Placebo contraindication criteria: Lactose intolerance
Where in France
- Centre Hospitalier Universitaire RouenRouen Cedex, FranceTaking people
About the trial
What the trial wants to find out
The main objective of this work is to evaluate the effect of the administration of an NK1 receptor antagonist (aprepitant) on aldosterone secretion in patients with obstructive sleep apnea syndrome (OSAS) and of arterial hypertension.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST, APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME - (APHOS3)
- Plain-language title
- Tests aprepitant effect on aldosterone in sleep apnea with high blood pressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 March 2026